Varian secures IDE for new Flash clinical trial

2020 01 30 01 49 9107 Varian Astro 2019 400

Siemens Healthineers radiation therapy unit Varian has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) for a new clinical trial evaluating its Flash therapy technology.

Building on clinical evidence from the initial FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases (FAST-01) clinical trial, FAST-02 will include bone metastases in the chest, according to Varian.

The trial, which will be conducted at Cincinnati Children's/UC Health Proton Therapy Center, is expected to enroll 10 patients with painful thoracic bone metastases. Led by principal investigator Dr. John Breneman, the researchers will assess treatment-related side effects and treatment efficacy, Varian said.

Page 1 of 461
Next Page